Cargando…

Optimal biological dose: a systematic review in cancer phase I clinical trials

BACKGROUND: Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraisse, J., Dinart, D., Tosi, D., Bellera, C., Mollevi, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805102/ https://www.ncbi.nlm.nih.gov/pubmed/33441097 http://dx.doi.org/10.1186/s12885-021-07782-z

Ejemplares similares

GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
por: Dinart, D., et al.
Publicado: (2020)

Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
por: Takahashi, Ami, et al.
Publicado: (2021)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update
por: Bautista, Francisco, et al.
Publicado: (2017)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs
por: Li, Chen, et al.
Publicado: (2022)

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)

Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma
por: Calzetta, Luigino, et al.
Publicado: (2022)

Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
por: Ursino, Moreno, et al.
Publicado: (2017)

Systematic review of first-in-human and early phase clinical trials for surgically implantable biological mitral valve substitutes
por: Sazzad, Faizus, et al.
Publicado: (2023)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)

Phase I oncology trials incorporating patient choice of dose
por: Huson, L W
Publicado: (2012)

Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials
por: Dunn, David T., et al.
Publicado: (2023)

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
por: Nurgat, Z A, et al.
Publicado: (2005)

A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
por: Xu, Jin, et al.
Publicado: (2022)

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
por: Darragh, Laurel B., et al.
Publicado: (2022)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Phase I Cancer Clinical Trials
por: Ledermann, J A
Publicado: (2007)

Dose Optimization of Colistin: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2021)

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
por: Assenat, E., et al.
Publicado: (2021)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial
por: Naviaux, Robert K., et al.
Publicado: (2017)

Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
por: Felix, Arthur, et al.
Publicado: (2021)

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
por: Aiken, Robert, et al.
Publicado: (2017)

A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
por: Li, Zhaohang, et al.
Publicado: (2023)

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
por: Stephenson, Christopher M., et al.
Publicado: (2013)

Random‐effects meta‐analysis for systematic reviews of phase I clinical trials: Rare events and missing data
por: Kim, Mi‐Ok, et al.
Publicado: (2016)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Rubens, R. D., et al.
Publicado: (1991)

A systematic review of pediatric clinical trials of high dose vitamin D
por: Nama, Nassr, et al.
Publicado: (2016)

Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer
por: Mader, Emily K, et al.
Publicado: (2013)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
por: Darragh, Laurel B., et al.
Publicado: (2022)

Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
por: Gattoc, Leda, et al.
Publicado: (2016)

Impact of dose feasibility on the conduct of phase I trials of adoptive cell therapy
por: Bagley, Evan M., et al.
Publicado: (2021)

Experimental designs for phase I and phase I/II dose-finding studies
por: O'quigley, J, et al.
Publicado: (2006)

Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer
por: Horton, Bethany Jablonski, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mpu5n1th87abu5vh3dvqbai9t4